. We have used this method to compare two antibody preparations in the clinical development of RIT. RIT had produced good response rates in radiosensitive tumours such as lymphoma when large amounts of radionuclide are given (Kaminski et al., 1993; Press et al., 1993). However, common epitheial tumours such as colorectal and breast carcinoma have not yet been treated so successfully because of their greater radioresistance, which diminishes the therpeutic ratio. In spite of this, responses to therapy have been reported , and it is likely that moderate increases in efficency in delivery of antibodymediated delivery of radiation could establish radioimmunotherapy as a useful form of therapy for metastatic colorectal carcinoma.
Radioimmunotherapy (RIT) uses an antibody delivery
system to target a tumour site with radiation. A number of beta-emitting radionuclides may be conjugated to antibody for this treatment. Iodine 131 (131') is valable for development of RIT because it has a beta emission of moderate energy capable of killing tumour cells over a range of up to 40 cell diameters and a gamma emission of energy 364 keV, which can be imaged with a gamma camera for quantification of biodistribution.
While it has been relatively easy to perform biodistribution studies in experimntal animals, there has not until now been a satisfactory way to obtain quantitative information about antibody distribution in man. We have developed a method for accurate quantification of 13I distribution which incorporates corrections for Compton scatter and attenuation (Green et al., 1990) . We have used this method to compare two antibody preparations in the clinical development of RIT. RIT had produced good response rates in radiosensitive tumours such as lymphoma when large amounts of radionuclide are given (Kaminski et al., 1993; Press et al., 1993) . However, common epitheial tumours such as colorectal and breast carcinoma have not yet been treated so successfully because of their greater radioresistance, which diminishes the therpeutic ratio. In spite of this, responses to therapy have been reported , and it is likely that moderate increases in efficency in delivery of antibodymediated delivery of radiation could establish radioimmunotherapy as a useful form of therapy for metastatic colorectal carcinoma.
Intact IgG antibodies with a molcular weight (MW) of 150 kilodaltons (kDa) may not penetrate well from blood through endothelium and extravascular tissues to the tumour (Yokota et al., 1992) . It is proposed that F(ab% antibodies (MW 100 kDa) will achieve more effective penetration because of their smaler molcular size and that this will significantly improve the prospects for effective radioimmunotherapy of colorectal cancer. Previous studies in animal tumour models of colorectal carinoma have shown that F(ab% antibodies labelled with 13'I give superior tumour to blood ratios than is achieved in therapy with intact antibody (Wahl et al., 1983; Buchegger et al., 1990; Pedley et al., 1993) . This hypothesis has been investigated in man by comparing the F(ab% fiagment with the intact version of the same antibody for RHT in patients with colorectal carcinoma.
PadeUs a h
Patients Ten patients with a raised serum CEA were given repeated injections of '31I-labelled anti_CEA intact IgG (A5B7) (serum CEA up to 622 sg 1-', median 117.5). The next nine patients were given '311-labelled anti-CEA A5B7 fragment F(ab'k (serum CEA up to 390ggl-1, median 79). To suppress the immune response to mouse IgG, cyclosporin A was given to all patients (Lermnann et al., 1988) . All patients had unresectable, locally recurrent or metastatic tumours and performance status 0-2 (WHO 1979 criteria) and gave written, informed consent. The study was approved by ethics committee and covered by ARSAC licence.
The serum level of human anti-mouse IgG antibody was negative before therapy, assayed as described previously (Ledermann et al., 1988) . A full blood count and renal, liver and thyroid function tests were performed at regular intervals. All patients had a negative intradermal test with loig of antibody prior to therapy. The thyroid was blocked with potassium iodide 180mg given orally 8 hourly for 14 days and potassium perchlorate 200mg 6 hourly for 4 days. Details of patients are given in Table . Anti-CEA antibody The mouse MAb (ASB7) was raised against CEA (Harwood et al., 1986) . It was purified from supernatant culture by protein A chromatography and shown to be free from ag- gregates by fast protein liquid chromatography (FPLC) (Ledermann et al., 1988) . Antibody production and preclinical toxicology were performed in accordance with the CRC Operation Manual (1986). The F(ab% fragment was produced from the intact MAb A5B7 anti-CEA by digestion with pepsin (Lamoyi & Nisonoff, 1983 ) and presented in a sterile (50mM phosphate) buffer and purified by protein A and gel filtration. Radioiodination was performed by the N-bromosuccinamide method (Adam, 1989 (MIRD pamphkt No. 11, 1975) .
Antibody distribution in tumour and normal tissue was determined by decay correcting the measured activity (MBq kg-') expressed as a percentage of the injected radioactivity and plotted against time. Mean patient distribution corresponding to median gamma-camera imaging times was estimated from the measured distribution data.
Antibody clearance was alculated by assuming a biphasic exponential curve fit to the serial tissue and blood data. The claanc phase is taken at greater than 24 h and data points after 24 h used to estimate the cearance half-life (t). Statistical analysis of the two patient groups was performed uing the non-parametnc Mann-Whitney U test. Figure 2 shows specific localisation in patient 3 (Table I) (Figure 3b and c).
'3'1-labelled antibody to CEA has been shown to localise well in colonic xenografts in nude mice and to significantly inhibit their growth (Pedley et al., 1991) . Although siilar tumourto-normal tissues ratios are achieved in mice and humans given the same antibody (Begent & Pedley, 1990) , the Table I ) who reeived intact A5B7. (Pedley et al., 1987) .
Human tumour xenografts used in mice are selected for their good loalisation of antibody, whereas there is great variation in localisation between individual patients (Boxer et al., 1992) . Neverthekss, evidence of tumour responses were seen in the patients in this and other studies . One of the limitations of RIT is the low dose rate achieved in the tumour. It has been estimated that, below a certain threshold dose rate, tumour growth rate will exceed cell kill rate (Fowler, 1990 (Badger et al., 1985; Bigler et al., 1986; Buchegger et al., 1990) (Arend & Mannikr 1972) .
The data presented are the first in patients to suggest a more rapid penetration of the F(ab% into tumours as compared with intact antibody. It is proposed that the faster penetration of the fragment is the result of its smaler mokcular weight, and this is consient with the finding that small molcular size in antibodies results in improved penetration in tumour animals models (Yokota et al., 1992) and in tumour spheroids (Sutherland et al., 1987; Sunters et al., 1992) . Sunters et al. (1992) showed that further reductions in molecular size of antibody may produce even more rapid tumour penetration. In animal model studies F(ab% cleared more rapidly from the circulation than intact antibody, making it difficult to assess the contribution of molcular size to tumour uptake since uptake is in part dependent on the availability of antibody in the circulation.
The observations in our study make it possible to see the effect of reducing moleular size on tumour penetration in man because the clarance from pLam of the F(ab% and intact antibody was very similar. Mocules smaler than F(ab% can be expected to clear more rapidly than F(ab% in man, with the result that the absolute amount of antibody delvered to the tumour will probably be less. F(ab)2 may therefore be a good compromise as a therapeutic molecule, giving high absolute amounts of radioantibody in the tumour with rapid penetration.
The overall improvement in initial uptake and therapeutic ratio associated with the administration of the F(ab')2 antibody has important implications for the future design of antibody-targeted therapy.
